107 related articles for article (PubMed ID: 23670283)
1. An evaluation of the anti-tumor efficacy of oleanolic acid-loaded PEGylated liposomes.
Tang S; Gao D; Zhao T; Zhou J; Zhao X
Nanotechnology; 2013 Jun; 24(23):235102. PubMed ID: 23670283
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C
Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer.
Kim CE; Lim SK; Kim JS
J Control Release; 2012 Jan; 157(2):190-5. PubMed ID: 21963773
[TBL] [Abstract][Full Text] [Related]
5. Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery.
Gao D; Tang S; Tong Q
Int J Nanomedicine; 2012; 7():3517-26. PubMed ID: 22848175
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Vile RG; Uster PS; Peters AM; Stewart JS
Clin Cancer Res; 2000 Dec; 6(12):4939-49. PubMed ID: 11156255
[TBL] [Abstract][Full Text] [Related]
7. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
Kajiwara E; Kawano K; Hattori Y; Fukushima M; Hayashi K; Maitani Y
J Control Release; 2007 Jul; 120(1-2):104-10. PubMed ID: 17509714
[TBL] [Abstract][Full Text] [Related]
8. Effect of a controlled-release drug delivery system made of oleanolic acid formulated into multivesicular liposomes on hepatocellular carcinoma in vitro and in vivo.
Luo Y; Liu Z; Zhang X; Huang J; Yu X; Li J; Xiong D; Sun X; Zhong Z
Int J Nanomedicine; 2016; 11():3111-29. PubMed ID: 27471381
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
[TBL] [Abstract][Full Text] [Related]
10. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.
Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W
J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of octreotide-modified oleanolic acid liposomes to somatostatin receptor overexpressing tumor cells.
Wang Q; Zhu R; Wang M; Xing S; Li L; He Y; Cao W; Gao D
Nanomedicine (Lond); 2017 Apr; 12(8):927-940. PubMed ID: 28338414
[TBL] [Abstract][Full Text] [Related]
12. Liposomal co-delivered oleanolic acid attenuates doxorubicin-induced multi-organ toxicity in hepatocellular carcinoma.
Sarfraz M; Afzal A; Raza SM; Bashir S; Madni A; Khan MW; Ma X; Xiang G
Oncotarget; 2017 Jul; 8(29):47136-47153. PubMed ID: 28525367
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
[TBL] [Abstract][Full Text] [Related]
14. Optimized formulation of multivesicular liposomes loaded with oleanolic acid enhanced anticancer effect in vitro.
Wang Y; Luo Y; Li C; Zhang X; Pi C; Yu L; Wang S; Zhong Z
Drug Des Devel Ther; 2017; 11():955-968. PubMed ID: 28392677
[TBL] [Abstract][Full Text] [Related]
15. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
16. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
17. Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behavior.
Li Y; Liu R; Yang J; Shi Y; Ma G; Zhang Z; Zhang X
Biomaterials; 2015 Feb; 41():1-14. PubMed ID: 25522960
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antitumor effects of folate-targeted ursolic acid stealth liposome.
Yang G; Yang T; Zhang W; Lu M; Ma X; Xiang G
J Agric Food Chem; 2014 Mar; 62(10):2207-15. PubMed ID: 24528163
[TBL] [Abstract][Full Text] [Related]
19. PEGylated liposomes as delivery systems for Gambogenic acid: Characterization and in vitro/in vivo evaluation.
Tang X; Sun J; Ge T; Zhang K; Gui Q; Zhang S; Chen W
Colloids Surf B Biointerfaces; 2018 Dec; 172():26-36. PubMed ID: 30125771
[TBL] [Abstract][Full Text] [Related]
20. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
